Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00456027
Recruitment Status : Completed
First Posted : April 4, 2007
Last Update Posted : June 10, 2011
Information provided by:
Diamyd Therapeutics AB

Brief Summary:
This is a study to investigate the safety of 20ug Diamyd® (rhGAD65 formulated in Alhydrogel®), administered subcutaneously four weeks apart in patients with Latent Autoimmune Diabetes in Adult (LADA).

Condition or disease Intervention/treatment Phase
Latent Autoimmune Diabetes in Adult (LADA) Drug: rhGAD65 formulated in Alhydrogel® (Diamyd®) Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 160 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Placebo-Controlled Study to Investigate the Impact of Diamyd® on the Diabetes Status of Patients With LADA (Latent Autoimmune Diabetes in Adult)
Study Start Date : December 2004
Actual Primary Completion Date : March 2008
Actual Study Completion Date : April 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Algeldrate
U.S. FDA Resources

Intervention Details:
    Drug: rhGAD65 formulated in Alhydrogel® (Diamyd®)
    20 micrograms of rhGAD65 formulated in Alhydrogel® administered subcutaneously twice 4 weeks apart

Primary Outcome Measures :
  1. The development over time of safety variables, i.e. injection site discomfort, vital signs, laboratory values and AEs/SAEs as well as development of diabetes status, i.e. HbA1c, C-peptide, blood glucose and insulin requirement. [ Time Frame: 30 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   30 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Male and female patients between 30-70 years of age diagnosed with type 2 diabetes within 5 years
  • Presence of GAD65 antibodies
  • Detectable C-peptide level
  • Patients requiring treatment with diet and/or oral hypoglycaemic agents (OHA)
  • Written informed Consent

Key Exclusion Criteria:

  • Treatment with insulin
  • Intolerance to OHA
  • Secondary diabetes mellitus
  • History of certain diseases or conditions (e.g. anaemia, epilepsy, head trauma, neurological disease, alcohol or drug abuse, HIV, hepatitis)
  • Treatment with any vaccine within one month prior to first Diamyd® dose or planned treatment with vaccine up to 2 months after the second Diamyd® dose
  • Participation in other clinical trials with a new chemical entity within the previous 3 months
  • Pregnancy (or planned pregnancy within one year after 2nd administration)
  • Presence of associated serious disease or condition which in the opinion of the investigator makes the patient non-eligible for the study
  • Significant illness other than diabetes within 2 weeks prior to first dosing
  • Unwillingness to comply with the provisions of the protocol
  • Clinically significant history of acute reaction to drugs in the past
  • Treatment with immunosuppressants

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00456027

Alingsås Hospital
Alingsås, Sweden
Falu Hospital
Falun, Sweden
Capio Lundby Hospital
Göteborg, Sweden
Helsingborg Hospital
Helsingborg, Sweden
Härnösand Hospital
Härnösand, Sweden
Karlstad Central Hospital
Karlstad, Sweden
Central Hospital, Kristianstad
Kristianstad, Sweden
Sunderby Hospital
Luleå, Sweden
University Hospital MAS
Malmö, Sweden
Vrinnevi Hospital
Norrköping, Sweden
Skellefteå Hospital
Skellefteå, Sweden
S:t Göran Hospital
Stockholm, Sweden
Stockholm South General Hospital
Stockholm, Sweden
Norrlands University Hospital
Umeå, Sweden
Uppsala University Hospital
Uppsala, Sweden
Växjö Central Hospital
Växjö, Sweden
Odensala Health Clinic
Östersund, Sweden
Sponsors and Collaborators
Diamyd Therapeutics AB
Principal Investigator: Carl-David Agardh, MD, phD University Hospital MAS, Malmö, Sweden

Responsible Party: Managing Director, Diamyd Therapeutics AB Identifier: NCT00456027     History of Changes
Other Study ID Numbers: D/P2/04/2
EUDRACT 2004-001998-25
First Posted: April 4, 2007    Key Record Dates
Last Update Posted: June 10, 2011
Last Verified: April 2007

Keywords provided by Diamyd Therapeutics AB:
Type 2 Diabetes
Latent Autoimmune Diabetes in Adult

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Latent Autoimmune Diabetes in Adults
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Aluminum Hydroxide
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents